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Effect of tumour necrosis factor on the uptake of specific and control
monoclonal antibodies in a human tumour xenograft model
G Rowlinson-Busza, A Maraveyas and AA Epenetos
Tumour Targeting Laboratory, Imperial Cancer Research Fund Oncology Unit, Royal Postgraduate Medical School,
Hammersmith Hospital, London W12 OHS, UK.
Summary The investigations reported in this paper aim to exploit tumour necrosis factor (TNF)-induced
vascular changes in an attempt to increase the tumour uptake of specific monoclonal antibody. The vascular
permeability to monoclonal antibody of a human tumour xenograft increased 2.6-fold by 1 h post injection of
2.5 x 103 U of TNF, although this effect was lost by 3 h. The normal tissues also demonstrated increased
vascular permeability to IgG, but to a lesser exent. Liver permeability increased 1.5-fold at I h but returned to
the control value by 6 h. Lung permeability increased 1.4-fold at 1 h post injection and returned to normal by
3 h. Muscle values were not significantly increased compared with controls. The blood activity was cleared
more quickly in the TNF-treated mice (ti = 101 h, compared with 121 h in control mice). This was probably
due to the increased vascular permeability in normal organs of treated mice. At I day and 3 days post
injection, the tumour uptake of the specific, but not the control, antibody was significantly increased by 25%
and 29% respectively. This resulted in an increase in the area under the tumour activity curve, and therefore
tumour radiation dose, of25% in treated compared with control mice. In addition, a consequence of the faster
blood clearance of the isotope in the TNF-treated mice was a reduction in the area under the blood activity
curve of 12%, thereby reducing systemic toxicity. The increase in vascular permeability to IgG following TNF
injection resulted in both specific and control antibodies having improved access to the tumour antigens, and a
transient increase in uptake was observed. Only in the case of the specific antibody was the increase
maintained, since this antibody binds to the available antigenic sites, whereas the control antibody was cleared
from the tumour without binding. No evidence of tumour necrosis was observed at the TNF doses given, nor
was there any toxicity to the mice.
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Vascular parameters such as blood flow, vascular perme-
ability and vascular volume are serious obstacles limiting
delivery of cytotoxic agents, including radiolabelled mono-
clonal antibodies, to tumours. Antibody access to tumour
cells may be limited by the tumour vasculature, with its
abnormal vessels and poor blood flow, and by regions of
high interstitial pressure (Jain and Baxter, 1988; Jain,
1991).
Tumour vascular permeability and blood flow have been
shown to correlate well with the uptake of monoclonal anti-
body in two different human tumour xenografts, the tumour
having twice the vascular permeability, resulting in a 5-fold
increase in antibody uptake (Sands et al., 1988). However,
few attempts have been made to alter tumour vascular para-
meters. Bomber et al. (1986) showed that the ,-blocker pro-
pranolol increases tumour perfusion and 67Ga uptake in a
mouse sarcoma. Smyth et al. (1987) have shown, in a xeno-
graft model, that both non-selective and cardioselective P-
adrenergic blocking agents increase the tumour-blood and
tumour-liver uptake ratios of '"I-labelled monoclonal anti-
body. Attard et al. (1991) used the corticosteroid dexa-
methasone to reduce tumour interstitial pressure and thereby
increase the tumour-background ratios in patients being
investigated by immunoscintigraphy. In one patient, two
metastatic deposits which were not visible without dexa-
methasone administration became visible after dexametha-
sone. Tumour vessels differ from normal vessels, particularly
in lacking sufficient smooth muscle to dilate or constrict in
response to drugs which have these effects on normal blood
vessels. By their selective action on normal blood vessels,
vasoactive drugs can change the tumour-normal tissue per-
fusion ratio (Chan et al., 1984).
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The cytokine interleukin 2 (IL-2) has been shown to in-
crease vascular permeability in normal organs, either alone
(Rosenstein et al., 1986) or in combination with lymphokine-
activated killer cells (Ettinghausen et al., 1988). Tumour
necrosis factor (TNF) is another cytokine which has been
shown to increase endothelial permeability directly, as
measured in endothelial cell monolayers (Royall et al., 1989).
In vivo, TNF is known to be a mediator of the inflammatory
response, and can lead to diffuse intravascular coagulation
with consequent changes in vascular permeability. This
damage to tumour vasculature induces ischaemia and hae-
morrhagic necrosis of the tumour within 24 h of administra-
tion, both in animal models (Palladino et al., 1987; van de
Wiel et al., 1989) and in a patient (Robertson et al., 1989).
This phenomenon was first exploited by Coley (1891), who
treated sarcoma patients by injecting bacterial cultures con-
taining Streptococcus erysipelatis, and noted tumour regres-
sions, some complete, in many patients. The principal active
constituent of Coley's toxins was undoubtedly lipopolysac-
charide (LPS), which is a potent inducer of TNF. Endotoxic
shock is associated with acute vascular endothelial injury
resulting in oedema (Brunson et al., 1955). Administration of
TNF to rats, in doses similar to those produced endogen-
ously in response to endotoxin, produces many of the symp-
toms of LPS toxaemia, including hypotension, pulmonary
inflammation and haemorrhage (Tracey et al., 1986). Pul-
monary vascular leakage has also been induced in sheep by
injection of TNF (Horvath et al., 1988). The barrier function
of the endothelium has been shown to be altered directly by
TNF (Sato et al., 1986). Aicher et al. (1990) have detected
changes in capillary permeability to gadolinium-conjugated
albumin in Meth A sarcomas in mice following TNF admini-
stration by means of contrast-enhanced magnetic resonance
imaging. van de Wiel et al. (1989) suggested that the broad
interference of tumour blood supply was the major cause of
necrosis of Meth A sarcomas in mice, since TNF did not
affect the Meth A cells in vitro. TNF has been shown to
increase vascular permeability in vivo immediately after injec-
tion (Kallinowski et al., 1989), and to affect the functional
and structural vascular volume in solid murine tumours (vande Wiel et al., 1990). Since poor vasculature is one of the
factors limiting antibody uptake in tumours (Jain, 1991), if
tumour vascular permeability could be increased by the
administration of TNF, this would facilitate antibody access
to tumour cell antigens. The investigations reported in this
paper aim to exploit these vascular changes in an attempt to
increase the tumour uptake of specific monoclonal anti-
body.
Materials and methods
Tumour model
The animals used in these studies were female nude mice of
mixed genetic background. They were bred under specific
pathogen-free conditions at the Imperial Cancer Research
Fund Animal Breeding Unit, South Mimms, Herts, UK, and
subsequently housed in sterile filter-top cages with sterile
bedding, and maintained on irradiated diet and autoclaved,
acidified water (pH 2.8).
The human tumour cell line HT29 was established in cell
culture in 1964 from a primary tumour in a female patient
with adenocarcinoma of the colon (Fogh and Trempe, 1975).
Tumour cells were cultured in RPMI-1640 medium contain-
ing 100 U ml-' penicillin and 1I00 Lgml-' streptomycin,
supplemented with 10% fetal calf serum (FCS) (Gibco,
Paisley, UK) at 37°C in a humidified atmosphere of 5%
carbon dioxide in air. Tumours were established in the right
flanks of the mice by subcutaneous injection of 5 x 106 cells
in 100pl of tissue culture medium. Animals were used for
experiment 3-4 weeks later, when the tumours were 6-8 mm
in diameter.
Antibodies
AUAI Monoclonal antibody AUA1, of the IgGI subclass,
was raised by immunising Balb/c mice with a human colon
carcinoma cell line (Arklie, 1981). AUA1 recognises a Mr
35 000 cell-surface glycoprotein, which is coded for by a gene
on chromosome 2, and which is only expressed in epithelial
cells (Spurr et al., 1986). The antibody reacts with a wide
range of tumours of epithelial origin such as breast, lung,
ovarian and gastrointestinal cancers, as well as with pro-
liferating epithelial cells in tissues such as normal colon, but
not with any non-epithelial tissues or tumours (Arklie, 1981;
Spurr et al., 1986). AUA1 was used as the specific antibody
for HT29 tumours.
HMFGJ This monoclonal antibody, also IgGI, was raised
in Balb/c mice using delipidated human milk fat globule as
immunogen (Taylor-Papadimitriou et al., 1981). The anti-
body is directed against a core protein determinant of a high
molecular weight glycoprotein (Mr>400000) normally pro-
duced by the lactating human mammary epithelial cell (Bur-
chell et al., 1987), but also found on some carcinomas, such
as those of breast, ovary and lung, but not with tumours of
mesenchymal tissue (Arklie et al., 1981). HMFG1 does not
bind to HT29 cells and was used as the irrelevant control
antibody.
Radiolabelling
Antibodies were labelled with '25I or '3'I (IMS 30 and IBS 30
respectively; Amersham International, Amersham, Bucks,
UK) to a specific activity of approximately 2 uCi uLg' using
the lodo-Gen method (Fraker and Speck, 1978).
Tumour necrosisfactor
Recombinant human tumour necrosis factor (specific activity
2.27 x 10 U mg-') was supplied by Asahi Chemical Indus-
try, Tokyo, Japan. Vials containing I05 U (44pg) in 1 ml of
water were stored at -20°C until immediately before use.
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Vascular studies
Vascular volume and vascular permeability to IgG were
determined for groups of control and TNF-treated mice
bearing s.c. HT29 xenografts. In the treated groups of mice,
2.5 x 103 U of TNF was injected i.v. at 1, 3, 6 and 24 h
before injection of radioactivity. Vascular volume and vas-
cular permeability were determined by the method of Song
and Levitt (1970), as modified by Sands et al. (1985), who
replaced 51Cr labelling of erythrocytes in vitro with
radiolabelling in vivo using 99!Tc (Pavel et al., 1977).
Groups of tumour-bearing mice were given i.v. injections
of 1.2pg of stannous fluoride in 1001tl of saline (Amerscan;
Amersham International) via a lateral tail vein. This was
followed after 30 min by an i.v. injection of a mixture of
25ftCi of [pTc]technetium pertechnetate and 10pCi (51tg)
of '25I-labelled HMFG1 antibody. Exactly 1 h post injection
of radioactivity, mice were killed by cervical dislocation, and
then tumour, liver, lung, muscle and a small sample ofblood
were removed, weighed and their 99ITc activity counted in a
'-counter. The low energy of the 125I emission does not
interfere with the detection of the 99'Tc activity. After allow-
ing sufficient time for the total decay of the 9'Tc (t1 = 6 h),
the tissues were counted again to determine their 125I content.
The vascular volume (VV) in units ofml blood per g oftissue
was calculated according to the formula:
V= Tc activity g' in tissue
`"T~c activity g'I in blood
The vascular permeability (VP) to IgG was determined by
calculating the amount of '251I-labelled irrelevant antibody
extravasated in 1 h, defined as the total plasma 1251I c.p.m. g'I
of tissue minus the intravascular plasma 1251I c.p.m. g- I tissue.
This was calculated in units of ml h'- g'- tissue as:
1251 cpm g' Intsu
VP = 25
m c.pm g' in blosdsueVV (1 - haematocrit)
The haematocrit (the percentage red cell volume in the
blood) was measured for several mice and found to agree
with the published value for mice of 40% (Green, 1979),
which was therefore used in all calculations. It has been
found, however, that the haematocrit in tissues is less than
that in the systemic circulation (O'Connor and Bale, 1984).
Since, in the present study, vascular permeability is compared
within the model in tumour and normal organs with and
without TNF administration, then if the haematocrit were
different from the systemic value this would result in a
systematic error in both measurements, as it is unlikely that
TNF administration alters the haematocrit.
The efficiency of red cell labelling was estimated by inject-
ing a group of mice with the same reagents at the same time
intervals as the experimental animals, and killing them by
exsanguination 1 h post injection of radioisotopes. The blood
was then centrifuged for 15 min at 2000 r.p.m. in a bench
centrifuge to isolate the red cells, which were washed twice
with phosphate-buffered saline (PBS). The 125I and 9"mTc
activities in the erythrocytes and plasma were measured.
Biodistribution
Nude mice bearing s.c. HT29 tumours were given a mixture
of 5pg each of '113-labelled AUA1 and '251-labelled HMFG1
antibodies i.v. In half the mice 2.5 x 103 U of TNF was
combined with the injected antibody. Groups of four treated
and control mice were dissected at times between 2 h and 6
days after antibody administration.
Statistical analysis
The statistical significance of the difference between means
was determined using the Student's t-test. A P-value <0.05
was considered to be significant.Effect of TNFon antibody uptake
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Results
Effect of TNF on tumour vascular parameters
The efficiency of red cell labelling in vivo was measured as
described. The washed cells contained 98% of the 9'Tc
activity, while the plasma contained 99.5% of the 1251I
activity, confirming the validity of the method. No evidence
of tumour necrosis was observed at the TNF doses given, nor
any toxicity to the mice.
Figures 1 and 2 show the effect of i.v. TNF (2.5 x 103 U)
on the vascular volume and vascular permeability to IgG in
treated and control mice bearing s.c. HT29 tumours. There
was no significant difference in the vascular volume in any
tissue at any time after i.v. TNF injection, except for liver at
1 and 3 h post injection. In contrast, the vascular perme-
ability of tumour was increased 2.6-fold by h post injection
of TNF (P<0.001), although this effect was lost by 3 h. The
normal tissues also demonstrated increased vascular perme-
ability but to a lesser exent. Liver permeability increased
1.5-fold at 1 h (P<0.02), but returned to the control value
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Figure 1 Vascular volume of HT29 tumour, lung, liver and
muscle in control mice (C) and in mice given 2.5 x 103 U of TNF
i.v. at 1 h, 3 h, 6 h and 24h before injection of the ['Tc]-
technetium pertechnetate and '251-labelled control antibody used
to measure these parameters. Each bar represents the mean and
s.d. of four mice.
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Figure 2 Vascular permeability of HT29 tumour, lun3g, liver and
muscle in control mice (C) and in mice given 2.5 x 10 U of TNF
i.v. at I h, 3 h, 6 h and 24 h before injection of the [p'Tc]tech-
netium pertechnetate and '25I-labelled control antibody employed
to measure these parameters. Each bar represents the mean and
s.d. of four mice.
by 6 h. Lung permeability increased 1.4-fold at 1 h post
injection (P< 0.02) and returned to normal by 3 h. Muscle
values did not increase significantly from controls.
Effect of TNF on antibody biodistribution
Tables I and II show the uptake of co-injected specific
(AUAI) and control (HMFGl) antibodies, with or without
the inclusion of 2.5 x 103 U of TNF, in mice bearing s.c.
HT29 xenografts. The blood activity was cleared more quick-
ly in the TNF-treated mice (for AUAl and HMFG1, respec-
tively, ti = 101 h and 101 h in TNF-treated mice compared
with 121 h and 115 h in control mice). Although there are
few time points used to calculate these values, since the same
result is observed for both antibodies, it may be a genuine
effect caused by increased vascular permeability in normal
organs oftreated mice. Two hours post injection, the tumour
uptake of both antibodies was increased 2-fold, however this
Table I Percentage of administered dose of specific (AUAI)
antibody per gram of tissue at the following times post injection. In
halfthe mice, 2.5 x 103 U ofTNF was included in the injectate. Each
value represents the mean ± s.d. of four mice
2h I day 3 days 6 days
With 2.5 x i10 U TNF
Blood 27.7 ± 3.2 15.8 ± 1.8 10.5 ± 0.7 6.9 ± 0.9
Tumour 8.1 ± 3.3 7.3 + 0.5* 6.2 + 0.6* 3.5 ± 0.8
Stomach 2.3 ± 0.4 2.1 0.7 1.8 0.9 0.9 0.1
Intestine 3.9 ± 1.4 1.9 0.3 1.2 0.2 0.9 0.1
Kidney 6.9 ± 0.6 3.8 0.6 2.8 0.6 1.5 0.3
Spleen 5.4±0.4 3.4±0.7 1.9±0.2 1.3±0.1
Lung 7.6 ± 0.6 6.6 ± 1.2** 3.6 + 0.4** 2.3 ± 0.5
Liver 8.9 ± 0.8 3.7 ± 0.7 2.3 ± 0.3 1.5 ± 0.2
Muscle 0.4± 0.1 0.7 0.1 0.6 0.1 0.4 0.1
Without TNF
Blood 28.4 3.7 15.4±0.6 13.7±2.7 7.4 1.5
Tumour 4.9 1.9 5.8 0.9 4.8 0.3 3.6 0.6
Stomach 2.0 0.2 1.8 0.2 1.7 0.1 0.9 0.2
Intestine 2.9 ± 0.2 1.6 ± 0.2 1.4 ± 0.1 0.9 ± 0.4
Kidney 6.4 ± 0.6 3.6 ± 0.2 2.9 ± 0.3 1.7 ± 0.5
Spleen 5.0 0.5 2.9 ± 0.3 2.6 ± 0.5 1.3 0.2
Lungs 7.9 ± 2.0 4.8 ± 0.1 5.3 ± 1.2 2.7 ± 0.5
Liver 7.4 0.7 3.7 0.2 3.4 0.9 1.6 0.4
Muscle 0.6±0.1 0.8±0.1 0.7±0.1 0.4±0.1
*P<0.05, **P<0.01 compared with untreated mice.
Table II Percentage of administered dose of control (HMFGI)
antibody per gram of tissue at the following times post injection. In
half the mice, 2.5 x 103 U ofTNF was included in the injectate. Each
value represents the mean ± s.d. of four mice
2h I day 3 days 6 days
With 2.5 x 103 U TNF
Blood 25.3 2.7 12.1 ± 1.1 8.1 0.5 5.3 0.6
Tumour 6.6 2.9 3.9 0.6 3.1 0.3 1.8 0.4
Stomach 3.7 ± 0.6** 2.5 ± 1.4 1.4 ± 0.7 0.7 ± 0.0
Intestine 4.8 ± 2.1 1.8 ± 0.4 1.0 ± 0.2 0.7 ± 0.0
Kidney 6.7 ± 0.7 3.1 ± 0.4 2.2 0.4 1.2 ± 0.2
Spleen 12.2 4.9 3.1 0.5 1.5 0.2 1.0 0.1
Lung 7.4±0.7 5.3± 1.1** 2.7±0.3** 1.7±0.4
Liver 11.5 0.9* 3.3 0.8 1.8 0.2 1.1 0.1
Muscle 0.4 0.1 0.6 0.1 0.5 0.0 0.3 0.0
Without TNF
Blood 25.7 2.8 11.6 0.6 10.5 2.5 5.6 0.6
Tumour 3.3 0.8 3.5 0.3 2.8 0.2 1.9 0.1
Stomach 2.7 0.4 1.7 0.2 1.3 0.1 0.7± 01
Intestine 3.1 0.2 1.4 0.3 1.1 0.1 0.7 0.2
Kidney 5.9 ± 0.5 2.9 ± 0.2 2.3 ± 0.3 1.3 ± 0.2
Spleen 7.7 1.1 2.7 0.4 2.2 0.6 1.0 0.1
Lungs 7.5 1.7 3.7 0.2 3.9 0.9 2.1 0.2
Liver 9.0±0.8 3.1±0.1 2.7±0.9 1.2±0.2
Muscle 0.5±0.1 0.6±0.1 0.6±0.2 0.3±0.0
*PJ<0.05, **P<0.01 compared with untreated mice.
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increased the cytotoxicity of an aminopterin-z
jugate in established tumours. Similarly, Meltoi
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Figure 3 Tumour uptake of AUAI antibody in
concurrent administration of 2.5 x 103 U of TNF (s(
in control mice (broken line). The increase in are
curve in treated mice is proportional to the increase
dose to the tumour.
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s on the data in vascular permeability were not measured. The importance
)ody (Table II) of tumour vascular permeability in relation to antibody
all time points uptake has been demonstrated by Sands et al. (1988), who
,cific antibody showed that a renal cell carcinoma xenograft having twice
by 1 day post the permeability of a breast tumour xenograft accumulated
n, the tumour five times the amount of monoclonal antibody by 24 h post
antibody was injection. In the present study, the TNF-induced elevation in
)ectively, com- tumour vascular permeability was short-lived, returning to
in an increase the untreated value by 3 h (Figure 2), so that the concurrent
and therefore administration of TNF and antibody is probably a major
,ompared with factor in the success of TNF in increasing the antibody
ition, a conse- uptake by tumour. Folli et al. (1993) have recently reported
isotope in the similar results using TNF and an anti-CEA antibody admin-
ider the blood istered i.v. or intra-tumorally in four different human colon
mic toxicity. carcinoma xenografts. Clearly, intra-tumour injection of
TNF would be suitable only for localised and not metastatic
disease. However, we have previously shown that intra-
tumour injection of radiolabelled monoclonal antibody alone
results in very high levels of radioactivity in the tumour
ollowing TNF (Rowlinson-Busza et al., 1991).
< and control Other properties of tumour necrosis factor may make it a
aour antigens, useful complement to radioimmunotherapy. The half-life of
zd. As seen in the radiolabelled antibody in the circulation was reduced in
Is the increase the TNF-treated mice, which would reduce the radiation
available anti- dose to bone marrow, and therefore myelotoxicity. A
n the tumour different inflammatory cytokine, IL-1, has been shown to be
-d a transient a radioprotector (Neta et al., 1986). Old (1987) proposed that
:reatment, but this may also be true of TNF, since TNF is one of the main
ake, since the mediators of endotoxin lipopolysaccharide action, and bact-
erial endotoxins have been shown to protect mice against
wn to increase lethal doses of X-rays (Smith et al., 1957). Neta et al. (1988)
nal tissue, re- have also shown that human recombinant TNF protects
ecific, but not lethally irradiated mice from death, but not as effectively as
it not normal IL-1 on a dose per mouse basis. In addition, they demon-
FNF increased strated that administration of the two cytokines together
i model, and resulted in additive radioprotection, implying that they each
antibody con- act through different radioprotective pathways. The same
n et al. (1993) group has also shown that administration of anti-TNF anti-
rNF increases bodies reduces survival in irradiated mice, suggesting that
onjugate in a natural levels ofTNF contribute to radioresistance ofnormal
n the present mice (Neta et al., 1991). In addition, the radioprotective
o observed in effect of systemically administered TNF could be blocked not
measured in only by anti-TNF antibody, but also by an antibody against
(1991) found the IL-1 receptor. Sl0rdal et al. (1989) have demonstrated
ood flow was TNF-dose-dependent enhancement of haematological recov-
trols. In their ery after irradiation in TNF-treated mice. A possible mech-
.e ofantibody anism for this radioprotection is the induction by TNF of
r xenografts, mRNA for manganous superoxide dismutase (MnSOD)
administered (Wong and Goeddel, 1988). MnSOD is an enzyme which
nall. Changes protects against oxidative damage by potentially toxic
superoxide radicals, which can be produced by irradiation.
Since the haematopoietic system is much more radiosensitive
than the tumour cells, then this property of TNF and the
more rapid blood clearance of radioactivity should selectively
protect against myelosuppression during radioimmuno-
therapy, and allow a higher dose of radiation to be delivered
to the tumour.
The mice in the studies presented in this paper tolerated
2.5 x I03U (175 1rg m 2) of TNF well, although the T-cell
deficiency of nude mice may have accounted for the lack of
an inflammatory response. In addition, human TNF has been
shown to react with the murine TNF receptor 1 on tumour
and endothelial cells but not with the miirine TNF rernntnr - - , -sss&- lk'%1110 vtL& LIVL tVVLtl L11%, IIlllUllll 1 1o1 IV,eVLUl
2 on thymocytes and cytotoxic lymphocytes (Tartaglia et al.,
1991). Phase I clinical trials have shown that the maximum
tolerated single dose of TNF in humans is 350 Lg m2i.v.
(Abbruzzese et al., 1989). Thus, it should be possible to
increase the antibody uptake in tumours in patients with
6 cancer by the concurrent administration of a tolerable dose
of TNF. The additional inflammatory response in patients,
ice receiving not observed in athymic mice, may also facilitate antibody
Dlidline) and access to tumour.
-a under the The effect of TNF could be increased by targeting it
in radiation directly to the tumour, resulting in an increased local concen-
tration. Therefore, although TNF may be more toxic in
nJ u -Effect of TNF on antibody uptake
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humans than in nude mice, targeting an antibody-TNF
fusion protein to the tumour should allow lower doses to be
given systemically to achieve the same tumour dose. Hoogen-
boom et al. (1991) have produced a hybridoma capable of
secreting an antibody-TNF fusion protein which retains the
biological activities of both constituent molecules in vitro.
This type of fusion protein may be capable of specifically
increasing tumour vascular permeability without the increase
in normal tissue permeability observed in the studies reported
in this paper. A recombinant fusion protein of a single-chain
Fv region and IL-2 which retains the biological properties of
each constituent protein has been produced (Savage et al.,
1993). This method should also be suitable for TNF-sFv
fusions, since the gene for human TNF has been cloned and
expressed in Escherichia coli (Shirai et al., 1985).
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